爱默生物科技有限公司
厦门市翔安区民安街道莲亭路811号401
(+86) 0592-7080189
support@amogene.com
Product Description
Human iPSC line with SOD1 mutation at A4V.
Figure 1. iXCells human iPS cells are characterized by immunostaining with Oct4, Nanog, Sox2, SSEA4, TRA-1-60-R, TRA-1-81.
Figure 2. (A) iXCells human iPS cells are positive for the transcription factor Oct4 (green) and the surface marker SSEA4 (red). (B) iXCells human iPS cells are positive for the surface markers TRA-1-81 (green) and SSEA4 (red).
Figure 3.In vivo validation of iXCells human iPS cells by teratoma formation.
Figure 4.Karyotyping of iPSC Line generate by iXCells Biotechnologies.
Product Description
Tissue Origin | Human iPS Cells derived from dermal fibroblasts, adipose-derived stem cells, or peripheral blood mononuclear cells |
Package Size | 2 frozen vials; ~0.5-1.0 million cells/vial |
Shipped | Cryopreserved |
Storage | Liquid nitrogen |
Growth Properties | Adherent |
Media & Reagents |
Human iPSC Growth Medium (Cat # MD-0018) MEF Conditioned Medium (Cat # MD-0015) Human iPSC Feeder-Free Growth Medium (Cat # MD-0019) Human iPSC Xeno-Free Growth Medium (Cat#0074) iMEF Feeder (CF1), irradiated (Cat # 10MU-001) Matrigel Coated Plates (Cat # MD-0023) |
References
[1] Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011 May; 8(5):409-12.
[1] Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011 May; 8(5):409-12.
Biological | |
---|---|
Species | Human (Normal) |